Prasugrel (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Prasugrel" in English language version.

refsWebsite

Global rank English rank

21nih.gov

4^th place

17doi.org

2^nd place

7semanticscholar.org

11^th place

8^th place

3web.archive.org

1^st place

3fda.gov

447^th place

338^th place

2europa.eu

68^th place

117^th place

1canada.ca

1,712^th place

1,063^rd place

1lilly.com

low place

1unizar.es

low place

1theheart.org

low place

canada.ca

health-products.canada.ca

"Product information -Effient". Health Canada. 2021. Retrieved 18 February 2021.

doi.org

Baker WL, White CM (2009). "Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes". American Journal of Cardiovascular Drugs. 9 (4): 213–229. doi:10.2165/1131209-000000000-00000. PMID 19655817. S2CID 37160513.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. (November 2007). "Prasugrel versus clopidogrel in patients with acute coronary syndromes". The New England Journal of Medicine. 357 (20): 2001–2015. doi:10.1056/NEJMoa0706482. PMID 17982182.{{cite journal}}: CS1 maint: overridden setting (link)
Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, et al. (August 2016). "National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016". The Medical Journal of Australia. 205 (3): 128–133. doi:10.5694/mja16.00368. PMID 27465769. S2CID 13014429.{{cite journal}}: CS1 maint: overridden setting (link)
Bellemain-Appaix A, Kerneis M, O'Connor SA, Silvain J, Cucherat M, Beygui F, et al. (October 2014). "Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis". BMJ. 349 (aug06 2): g6269. doi:10.1136/bmj.g6269. PMC 4208629. PMID 25954988.{{cite journal}}: CS1 maint: overridden setting (link)
Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. (September 2013). "Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes". The New England Journal of Medicine. 369 (11): 999–1010. doi:10.1056/NEJMoa1308075. PMID 23991622. S2CID 205095981.{{cite journal}}: CS1 maint: overridden setting (link)
Lordkipanidzé M, Marquis-Gravel G, Tanguay JF, Mehta SR, So DY (June 2021). "Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada". CJC Open. 3 (6): 814–821. doi:10.1016/j.cjco.2020.11.021. PMC 8209390. PMID 34169260.
John J, Koshy SK (2012). "Current oral antiplatelets: focus update on prasugrel". Journal of the American Board of Family Medicine. 25 (3): 343–349. doi:10.3122/jabfm.2012.03.100270. PMID 22570398.
Demcsák A, Lantos T, Bálint ER, Hartmann P, Vincze Á, Bajor J, et al. (19 November 2018). "PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis". Frontiers in Physiology. 9: 1550. doi:10.3389/fphys.2018.01550. PMC 6252380. PMID 30510515.{{cite journal}}: CS1 maint: overridden setting (link)
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. (September 2009). "Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials". Lancet. 374 (9694): 989–997. doi:10.1016/S0140-6736(09)61525-7. PMID 19726078. S2CID 205956050.{{cite journal}}: CS1 maint: overridden setting (link)
Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, et al. (September 2016). "Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial". The American Journal of Medicine. 129 (9): 1002–1005. doi:10.1016/j.amjmed.2016.03.042. PMID 27143321.{{cite journal}}: CS1 maint: overridden setting (link)
Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, et al. (January 2007). "A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation". American Heart Journal. 153 (1): 66.e9–66.16. doi:10.1016/j.ahj.2006.10.010. PMID 17174640.{{cite journal}}: CS1 maint: overridden setting (link)
Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. (December 2007). "Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial". Circulation. 116 (25): 2923–2932. doi:10.1161/CIRCULATIONAHA.107.740324. PMID 18056526. S2CID 8226182.{{cite journal}}: CS1 maint: overridden setting (link)
Ruff CT, Giugliano RP, Antman EM, Murphy SA, Lotan C, Heuer H, et al. (March 2012). "Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world". International Journal of Cardiology. 155 (3): 424–429. doi:10.1016/j.ijcard.2010.10.040. PMID 21093072.{{cite journal}}: CS1 maint: overridden setting (link)
Silvano M, Zambon CF, De Rosa G, Plebani M, Pengo V, Napodano M, et al. (February 2011). "A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty". Journal of Thrombosis and Thrombolysis. 31 (2): 233–234. doi:10.1007/s11239-010-0533-x. PMID 21088983. S2CID 20617890.
Warlo EM, Arnesen H, Seljeflot I (December 2019). "A brief review on resistance to P2Y₁₂ receptor antagonism in coronary artery disease". Thrombosis Journal. 17 (1): 11. doi:10.1186/s12959-019-0197-5. PMC 6558673. PMID 31198410.
Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, et al. (April 2006). "Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450". Drug Metabolism and Disposition. 34 (4): 600–607. doi:10.1124/dmd.105.007989. PMID 16415119. S2CID 1698598.{{cite journal}}: CS1 maint: overridden setting (link)
Kurokawa T, Fukami T, Yoshida T, Nakajima M (March 2016). "Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog". Drug Metabolism and Disposition. 44 (3): 409–416. doi:10.1124/dmd.115.068221. PMID 26718653.

europa.eu

ema.europa.eu

"Efient EPAR". European Medicines Agency (EMA). 25 February 2009. Retrieved 5 September 2024.
"European Public Assessment Report for Efient" (PDF). EMA. 2009.

fda.gov

"Effient (prasugrel hydrochloride) Prescribing Information". U.S. Food and Drug Administration (FDA). September 2011. Archived from the original on 18 January 2017. Retrieved 16 December 2019.
"FDA Announces New Boxed Warning on Plavix: Alerts patients, health care professionals to potential for reduced effectiveness" (Press release). U.S. Food and Drug Administration (FDA). 12 March 2010. Archived from the original on 15 March 2010. Retrieved 13 March 2010.
"FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug". U.S. Food and Drug Administration (FDA). 12 March 2010. Retrieved 13 March 2010.

lilly.com

pi.lilly.com

"Efient (prasugrel) tablets: Highlights of prescribing information" (PDF). Eli Lilly. 2011. Archived from the original (PDF) on 31 January 2012.

nih.gov

pubmed.ncbi.nlm.nih.gov

Baker WL, White CM (2009). "Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes". American Journal of Cardiovascular Drugs. 9 (4): 213–229. doi:10.2165/1131209-000000000-00000. PMID 19655817. S2CID 37160513.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. (November 2007). "Prasugrel versus clopidogrel in patients with acute coronary syndromes". The New England Journal of Medicine. 357 (20): 2001–2015. doi:10.1056/NEJMoa0706482. PMID 17982182.{{cite journal}}: CS1 maint: overridden setting (link)
Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, et al. (August 2016). "National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016". The Medical Journal of Australia. 205 (3): 128–133. doi:10.5694/mja16.00368. PMID 27465769. S2CID 13014429.{{cite journal}}: CS1 maint: overridden setting (link)
Bellemain-Appaix A, Kerneis M, O'Connor SA, Silvain J, Cucherat M, Beygui F, et al. (October 2014). "Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis". BMJ. 349 (aug06 2): g6269. doi:10.1136/bmj.g6269. PMC 4208629. PMID 25954988.{{cite journal}}: CS1 maint: overridden setting (link)
Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. (September 2013). "Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes". The New England Journal of Medicine. 369 (11): 999–1010. doi:10.1056/NEJMoa1308075. PMID 23991622. S2CID 205095981.{{cite journal}}: CS1 maint: overridden setting (link)
Lordkipanidzé M, Marquis-Gravel G, Tanguay JF, Mehta SR, So DY (June 2021). "Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada". CJC Open. 3 (6): 814–821. doi:10.1016/j.cjco.2020.11.021. PMC 8209390. PMID 34169260.
John J, Koshy SK (2012). "Current oral antiplatelets: focus update on prasugrel". Journal of the American Board of Family Medicine. 25 (3): 343–349. doi:10.3122/jabfm.2012.03.100270. PMID 22570398.
Demcsák A, Lantos T, Bálint ER, Hartmann P, Vincze Á, Bajor J, et al. (19 November 2018). "PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis". Frontiers in Physiology. 9: 1550. doi:10.3389/fphys.2018.01550. PMC 6252380. PMID 30510515.{{cite journal}}: CS1 maint: overridden setting (link)
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. (September 2009). "Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials". Lancet. 374 (9694): 989–997. doi:10.1016/S0140-6736(09)61525-7. PMID 19726078. S2CID 205956050.{{cite journal}}: CS1 maint: overridden setting (link)
Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, et al. (September 2016). "Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial". The American Journal of Medicine. 129 (9): 1002–1005. doi:10.1016/j.amjmed.2016.03.042. PMID 27143321.{{cite journal}}: CS1 maint: overridden setting (link)
Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, et al. (January 2007). "A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation". American Heart Journal. 153 (1): 66.e9–66.16. doi:10.1016/j.ahj.2006.10.010. PMID 17174640.{{cite journal}}: CS1 maint: overridden setting (link)
Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. (December 2007). "Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial". Circulation. 116 (25): 2923–2932. doi:10.1161/CIRCULATIONAHA.107.740324. PMID 18056526. S2CID 8226182.{{cite journal}}: CS1 maint: overridden setting (link)
Ruff CT, Giugliano RP, Antman EM, Murphy SA, Lotan C, Heuer H, et al. (March 2012). "Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world". International Journal of Cardiology. 155 (3): 424–429. doi:10.1016/j.ijcard.2010.10.040. PMID 21093072.{{cite journal}}: CS1 maint: overridden setting (link)
Silvano M, Zambon CF, De Rosa G, Plebani M, Pengo V, Napodano M, et al. (February 2011). "A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty". Journal of Thrombosis and Thrombolysis. 31 (2): 233–234. doi:10.1007/s11239-010-0533-x. PMID 21088983. S2CID 20617890.
Warlo EM, Arnesen H, Seljeflot I (December 2019). "A brief review on resistance to P2Y₁₂ receptor antagonism in coronary artery disease". Thrombosis Journal. 17 (1): 11. doi:10.1186/s12959-019-0197-5. PMC 6558673. PMID 31198410.
Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, et al. (April 2006). "Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450". Drug Metabolism and Disposition. 34 (4): 600–607. doi:10.1124/dmd.105.007989. PMID 16415119. S2CID 1698598.{{cite journal}}: CS1 maint: overridden setting (link)
Kurokawa T, Fukami T, Yoshida T, Nakajima M (March 2016). "Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog". Drug Metabolism and Disposition. 44 (3): 409–416. doi:10.1124/dmd.115.068221. PMID 26718653.

ncbi.nlm.nih.gov

Bellemain-Appaix A, Kerneis M, O'Connor SA, Silvain J, Cucherat M, Beygui F, et al. (October 2014). "Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis". BMJ. 349 (aug06 2): g6269. doi:10.1136/bmj.g6269. PMC 4208629. PMID 25954988.{{cite journal}}: CS1 maint: overridden setting (link)
Lordkipanidzé M, Marquis-Gravel G, Tanguay JF, Mehta SR, So DY (June 2021). "Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada". CJC Open. 3 (6): 814–821. doi:10.1016/j.cjco.2020.11.021. PMC 8209390. PMID 34169260.
Demcsák A, Lantos T, Bálint ER, Hartmann P, Vincze Á, Bajor J, et al. (19 November 2018). "PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis". Frontiers in Physiology. 9: 1550. doi:10.3389/fphys.2018.01550. PMC 6252380. PMID 30510515.{{cite journal}}: CS1 maint: overridden setting (link)
Warlo EM, Arnesen H, Seljeflot I (December 2019). "A brief review on resistance to P2Y₁₂ receptor antagonism in coronary artery disease". Thrombosis Journal. 17 (1): 11. doi:10.1186/s12959-019-0197-5. PMC 6558673. PMID 31198410.

semanticscholar.org

api.semanticscholar.org

Baker WL, White CM (2009). "Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes". American Journal of Cardiovascular Drugs. 9 (4): 213–229. doi:10.2165/1131209-000000000-00000. PMID 19655817. S2CID 37160513.
Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, et al. (August 2016). "National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016". The Medical Journal of Australia. 205 (3): 128–133. doi:10.5694/mja16.00368. PMID 27465769. S2CID 13014429.{{cite journal}}: CS1 maint: overridden setting (link)
Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. (September 2013). "Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes". The New England Journal of Medicine. 369 (11): 999–1010. doi:10.1056/NEJMoa1308075. PMID 23991622. S2CID 205095981.{{cite journal}}: CS1 maint: overridden setting (link)
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. (September 2009). "Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials". Lancet. 374 (9694): 989–997. doi:10.1016/S0140-6736(09)61525-7. PMID 19726078. S2CID 205956050.{{cite journal}}: CS1 maint: overridden setting (link)
Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. (December 2007). "Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial". Circulation. 116 (25): 2923–2932. doi:10.1161/CIRCULATIONAHA.107.740324. PMID 18056526. S2CID 8226182.{{cite journal}}: CS1 maint: overridden setting (link)
Silvano M, Zambon CF, De Rosa G, Plebani M, Pengo V, Napodano M, et al. (February 2011). "A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty". Journal of Thrombosis and Thrombolysis. 31 (2): 233–234. doi:10.1007/s11239-010-0533-x. PMID 21088983. S2CID 20617890.
Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, et al. (April 2006). "Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450". Drug Metabolism and Disposition. 34 (4): 600–607. doi:10.1124/dmd.105.007989. PMID 16415119. S2CID 1698598.{{cite journal}}: CS1 maint: overridden setting (link)

theheart.org

O'Riordan M. "Switching from clopidogrel to prasugrel further reduces platelet function". TheHeart.org. Retrieved 1 April 2011.

unizar.es

zaguan.unizar.es

Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, et al. (September 2016). "Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial". The American Journal of Medicine. 129 (9): 1002–1005. doi:10.1016/j.amjmed.2016.03.042. PMID 27143321.{{cite journal}}: CS1 maint: overridden setting (link)

web.archive.org

"Effient (prasugrel hydrochloride) Prescribing Information". U.S. Food and Drug Administration (FDA). September 2011. Archived from the original on 18 January 2017. Retrieved 16 December 2019.
"Efient (prasugrel) tablets: Highlights of prescribing information" (PDF). Eli Lilly. 2011. Archived from the original (PDF) on 31 January 2012.
"FDA Announces New Boxed Warning on Plavix: Alerts patients, health care professionals to potential for reduced effectiveness" (Press release). U.S. Food and Drug Administration (FDA). 12 March 2010. Archived from the original on 15 March 2010. Retrieved 13 March 2010.